Raloxifene 4'-glucuronide-d4

CAT:
804-HY-135582S
Size:
Inquire

For Laboratory Research Only. Not for Clinical or Personal Use.

  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Raloxifene 4'-glucuronide-d4 - image 1

Raloxifene 4'-glucuronide-d4

  • UNSPSC Description:

    Raloxifene 4'-glucuronide-d4 is deuterated labeled Raloxifene 4'-glucuronide (HY-135582). Raloxifene 4'-glucuronide is a primary metabolite of Raloxifene. Raloxifene 4'-glucuronide formation is mediated mostly by UGT1A10 and UGT1A8. Raloxifene 4'-glucuronide binds to estrogen receptor with an IC50 of 370 μM. [1][2]. Raloxifene is a selective estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression[3].
  • Target Antigen:

    Estrogen Receptor/ERR; Isotope-Labeled Compounds
  • Type:

    Isotope-Labeled Compounds
  • Related Pathways:

    Others;Vitamin D Related/Nuclear Receptor
  • Applications:

    Metabolism-protein/nucleotide metabolism
  • Field of Research:

    Endocrinology
  • Solubility:

    10 mM in DMSO
  • Smiles:

    O=C(C1=CC=C(C=C1)OC([2H])([2H])C([2H])([2H])N2CCCCC2)C3=C(C4=CC=C(C=C4)O[C@@H]5O[C@@H]([C@H]([C@@H]([C@H]5O)O)O)C(O)=O)SC6=CC(O)=CC=C63
  • Molecular Weight:

    653.73
  • References & Citations:

    [1]Izgelov D, et al. The Effect of Piperine Pro-Nano Lipospheres on Direct Intestinal Phase II Metabolism: The Raloxifene Paradigm of Enhanced Oral Bioavailability. Mol Pharm. 2018 Apr 2;15(4):1548-1555.|[2]Kemp DC, et al. Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metab Dispos. 2002 Jun;30(6):694-700.|[3]Yang NN, et al. Estrogen and raloxifene stimulate transforming growth factor-beta 3 gene expression in rat bone: a potential mechanism for estrogen- or raloxifene-mediated bone maintenance. Endocrinology. 1996 May;137(5):2075-84.|[4]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
  • Shipping Conditions:

    Room temperature
  • Clinical Information:

    No Development Reported
  • CAS Number:

    1279033-52-1